Drug intelligence / Profile preview

CP215

Development stage: Preclinical
Lead developer: Consegna Pharma
Administration: Parenteral

Overview

CP215 is a preclinical-stage long-acting injectable (LAI) formulation developed by Consegna Pharma as a medical countermeasure for Acute Radiation Syndrome (ARS). The drug is designed using Consegna's proprietary computational PLGA formulation platform to provide a sustained 7-day release of its active ingredient following a single administration. It is intended for use as a prophylactic or post-exposure treatment to mitigate the systemic effects of high-dose radiation exposure, aiming to improve survival and reduce morbidity in radiological or nuclear emergency scenarios.

Beyond the preview

Go deeper on CP215.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP215.

Explore the full profile